ArticleGenes & genomics2026
Anticancer activity of himantormione B: a new depsidone from the Antarctic lichen Himantormia lugubris, in colorectal cancer.
Article in Genes & genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent studies have highlighted the pharmaceutical potential of lichen extracts, particularly with respect to their anticancer properties. Lichens, symbiotic organisms composed of fungi and algae or cyanobacteria, have long been utilized in traditional medicine. Accumulating evidence from recent investigations further supports the potential therapeutic applications of lichen-derived compounds in a variety of diseases, including cancer.
objectiveThe study aimed to investigate the anticancer activity of himantormione B, a newly identified secondary metabolite isolated from the Antarctic lichen Himantormia lugubris, in the human colorectal cancer cell lines HCT116 and HT-29.
methodsCell viability was assessed using an MTS assay in MRC-5, HCT116, and HT-29 cells. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and immunoblot analyses were performed to evaluate the expression levels of apoptosis-related genes, including BAX, BCL2, PUMA, and CASP3. To further investigate the apoptotic effects of himantormione B in HCT116 and HT-29 cells, cells were stained with Annexin V-FITC and propidium iodide (PI), followed by flow cytometric analysis (FACS). In addition, in silico ADMET analyses were conducted to determine whether himantormione B exhibits favorable drug-like properties and promising pharmacological potential.
resultsBased on our results, himantormione B exerted a significant cytotoxic effect on colorectal cancer cells compared with MRC-5 normal fibroblasts. Moreover, himantormione B induced apoptosis in a concentration-dependent manner by modulating the expression of apoptosis-related genes, including BAX, BCL-2, PUMA, and CASP3. Specifically, treatment with himantormione B significantly downregulated the expression of the anti-apoptotic gene BCL-2, while concomitantly upregulating the expression of the pro-apoptotic genes BAX and PUMA. In agreement with the flow cytometric analysis demonstrating himantormione B-induced apoptosis, we further observed a dose-dependent increase in cleaved caspase-3 levels. Given that caspase-3 is a key executioner caspase that promotes apoptotic progression and suppresses cell survival, these findings collectively indicate that himantormione B induces apoptosis via activation of the intrinsic apoptotic signaling pathway.
conclusionTaken together, the present study provides a comprehensive evaluation of the anticancer activity of himantormione B in colorectal cancer, highlighting its potential as a promising therapeutic candidate for targeted treatment strategies.
Indexed as
Identifiers
41915377What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.